Follow us on Twitter
twitter icon@FreshPatents


Immune Disorder patents

      

This page is updated frequently with new Immune Disorder-related patent applications.




 Detection of shed cd31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways patent thumbnailDetection of shed cd31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways
The present invention stems from the finding that the extracellular domain of cd31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of cd31. A method for detecting shed cd31 is further disclosed.
Institut National De La Sante Et De La Recherche Medicale (inserm)


 Pyridone and aza-pyridone compounds and methods of use patent thumbnailPyridone and aza-pyridone compounds and methods of use
Pyridone and aza-pyridone compounds of formula i are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating immune disorders such as inflammation mediated by btk kinase. Methods of using compounds of formula i for in intro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
Genentch Inc.


 Composition comprising probiotic bacteria for use in the treatment of immune disorders patent thumbnailComposition comprising probiotic bacteria for use in the treatment of immune disorders
The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis..
Probiotical S.p.a.


 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier patent thumbnailBacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.. .
Synlogic, Inc.


 Amido compounds as roryt modulators and uses thereof patent thumbnailAmido compounds as roryt modulators and uses thereof
And wherein n1, n2, r1a, r1b, r2, r3, r4, r5, and r6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease..

 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases patent thumbnailInduced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.


 Human antibodies that bind cd22 and uses thereof patent thumbnailHuman antibodies that bind cd22 and uses thereof
The present disclosure provides isolated monoclonal antibodies that specifically bind to cd22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.


 Fumarate compounds, pharmaceutical compositions thereof, and methods of use patent thumbnailFumarate compounds, pharmaceutical compositions thereof, and methods of use
Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

 Autoimmune disorder treatment using rxr agonists patent thumbnailAutoimmune disorder treatment using rxr agonists
The present specification provides rxr agonist compounds, compositions comprising such rxr agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such rxr agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.. .
Dartmouth College


 Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases patent thumbnailCompositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes..
The Children's Hospital Of Philadelphia


Methods to produce single glycoform antibodies

An enzymatic method is provided for restructuring an affinity ligand bound heterogenous glycoform antibody sample to a substantially homogenous single desired glycoform antibody sample for therapeutic uses and kits for performing the methods. A method for enzymatically altering the fc region of an affinity ligand bound antibody from a heterogenous glycoform to a substantially homogenous single glycoform comprises: contacting the affinity ligand bound heterogeneous glycoform antibody with a reaction buffer designed for a particular glycoform modification for a time sufficient and under conditions to modify the glycoform of the fc region to a substantially homogeneous single form; optionally adding one or more nucleotide sugars and/or cofactors; and releasing the substantially homogeneous single glycoform antibody sample from said affinity ligand.
The University Of Manitoba

Method of providing monoclonal auto-antibodies with desired specificity

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
Immunoqure Ag

Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides

This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
Mayo Foundation For Medical Education And Research

Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides

This document relates to inhibitors of g protein coupled receptor 6 kinase (grk6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.. .
Mayo Foundation For Medical Education And Research

Extracellular targeted drug conjugates

Extracellular drug conjugates (edcs) targeting an extracellular protein or portion thereof (e.g., cd38) and comprising a non-cleavable linker including one or two nitrogen heteroatoms are useful in the treatment of diseases such as cancer and immune disorders, including asthma.. .
Centrose, Llc

New compounds i

And their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or n-oxides, which are inhibitors of ssao activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of ssao activity is beneficial, such as inflammatory diseases and immune disorders..

Hydrophobically tagged janus kinase inhibitors and uses thereof

The present invention provides janus kinase inhibitors, such as compounds of formula (i) and formula (ii) wherein ry1 and ry2 comprise a tagged hydrophobic moiety rh. The compounds may covalently or non-covalently bind a kinase (e.g., janus kinase 3 (jak3)).
Dana-farber Cancer Institute, Inc.

Janus kinase inhibitors and uses thereof

The present invention provides kinase inhibitors, such as compounds of formula (i) and formula (ii). The compounds may covalently or non-covalently bind a kinase (e.g., janus kinase 3 (jak3)).
Dana-farber Cancer Institute, Inc.

Aav-based gene therapy for multiple sclerosis

Disclosed are aav viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed aav-based gene therapeutic regimen for treating and/or ameliorating autoimmune disorders such as multiple sclerosis.. .
University Of Florida Research Foundation, Inc

Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
The Johns Hopkins University

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .



Immune Disorder topics:
  • Immune Disorder
  • Autoimmune
  • Autoimmune Disorder
  • Autoimmune Disorders
  • Inflammation
  • Pharmaceutically Acceptable Salt
  • Pharmaceutically Acceptable Salts
  • Immune Disease
  • Immune Diseases
  • Antagonist
  • Immunosuppressive
  • Pathologic
  • Immunosuppressive Agents
  • Immunosuppressive Agent
  • Infectious


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immune Disorder for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disorder with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.1193

    file did exist - file did put3162

    8 - 1 - 59